Marialena Trivella

Marialena Trivella

Auto-generated profile, based on publicly available information

Marialena Trivella

Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2016 in JAMA
Verified
Journal Article
Closed access
PDF file
DIDespo Ierodiakonou
Despo Ierodiakonou
VGVanessa Garcia-Larsen
Vanessa Garcia-Larsen
ALAndrew Logan
Andrew Logan
AGAnnabel Groome
Annabel Groome
SCSergio Cunha
Sergio Cunha
RBRobert Boyle
Robert Boyle
This meta-analysis summarizes evidence about associations between timing of allergenic food introduction during infancy and risk of allergic or autoimmune disea

20 July 2016 in BMJ
Verified
Journal Article
Open access
PDF file
PGPaul Garner
Paul Garner
SHSally Hopewell
Sally Hopewell
JCJackie Chandler
Jackie Chandler
HMHarriet MacLehose
Harriet MacLehose
HSHolger J Schünemann
Holger J Schünemann
EWEd C Wilson
Ed C Wilson
Updating of systematic reviews is generally more efficient than starting all over again when new evidence emerges, but to date there has been no clear guidance on how to do this. This guidance helps authors of systematic reviews, commissioners, and editors decide when to update a systematic review, and then how to go about updating the review. Systematic reviews synthesise relevant research around a particular question. Preparing a systematic review is time and resource consuming, and provides a snapshot of knowledge at the time of incorporation of data from studies identified during the latest search. Newly identified studies can change the conclusion of a review. If they have not been included, this threatens the validity of the review, and, at worst, means the review could mislead. For patients and other healthcare consumers, this means that care and policy development might not be fully informed by the latest research; furthermore, researchers could be misled and carry out research in areas where no further research is actually needed.1 Thus, there are clear benefits to updating reviews, rather than duplicating the entire process as new evidence emerges or new methods develop. Indeed, there is probably added value to updating a review, because this will include taking into account comments and criticisms, and adoption of new methods in an iterative process.2 3 4 5 6 Cochrane has over 20 years of experience with preparing and updating systematic reviews, with the publication of over 6000 systematic reviews. However, Cochrane’s principle of keeping all reviews up to date has not been possible, and the organisation has had to adapt: from updating when new evidence becomes available,7 to updating every two years,8 to updating based on need and priority.9 This experience has shown that it is not possible, sensible, or feasible to …

12 July 2012 in BMJ
Verified
Journal Article
Open access
PDF file
RJR. Jeevan
R. Jeevan
DCD. A. Cromwell
D. A. Cromwell
MTM. Trivella
M. Trivella
GLG. Lawrence
G. Lawrence
OKO. Kearins
O. Kearins
JMJ. H. P. van der Meulen
J. H. P. van der Meulen
Objectives To examine whether rate of reoperation after breast conserving surgery is associated with patients’ characteristics and investigate whether reoperation rates vary among English NHS trusts. Design Cohort study using patient level data from hospital episode statistics. Setting English NHS trusts. Participants Adult women who had breast conserving surgery between 1 April 2005 and 31 March 2008. Main outcome measure Reoperation rates after primary breast conserving surgery within 3 months, adjusted using logistic regression for tumour type, age, comorbidity, and socioeconomic deprivation. Tumours were grouped by whether a carcinoma in situ component was coded at the time of the primary breast conserving surgery. Results 55 297 women had primary breast conserving surgery in 156 NHS trusts during the three year period. 11 032 (20.0%, 95% confidence interval 19.6% to 20.3%) women had at least one reoperation. 10 212 (18.5%, 18.2% to 18.8%) had one reoperation only; of these, 5943 (10.7%, 10.5% to 11.0%) had another breast conserving procedure and 4269 (7.7%, 7.5% to 7.9%) had a mastectomy. Of the 45 793 women with isolated invasive disease, 8229 (18.0%) had at least one reoperation. In comparison, 2803 (29.5%) of the 9504 women with carcinoma in situ had at least one reoperation (adjusted odds ratio 1.9, 95% confidence interval 1.8 to 2.0). Substantial differences were found in the adjusted reoperation rates among the NHS trusts (10th and 90th centiles 12.2% and 30.2%). Conclusion: One in five women who had breast conserving surgery in England had a reoperation. Reoperation was nearly twice as likely when the tumour had a carcinoma in situ component coded. Women should be informed of this reoperation risk when deciding on the type of surgical treatment of their breast cancer.

28 February 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
VGVanessa Garcia-Larsen
Vanessa Garcia-Larsen
DIDespo Ierodiakonou
Despo Ierodiakonou
KJKatharine Jarrold
Katharine Jarrold
SCSergio Cunha
Sergio Cunha
JCJennifer Chivinge
Jennifer Chivinge
RBRobert Boyle
Robert Boyle
There is uncertainty about the influence of diet during pregnancy and infancy on a child’s immune development. We assessed whether variations in maternal or infant diet can influence risk of allergic or autoimmune disease. Two authors selected studies, extracted data, and assessed risk of bias. Grading of Recommendations Assessment, Development and Evaluation (GRADE) was used to assess certainty of findings. We searched Medical Literature Analysis and Retrieval System Online (MEDLINE), Excerpta Medica dataBASE (EMBASE), Web of Science, Central Register of Controlled Trials (CENTRAL), and Literatura Latino Americana em Ciências da Saúde (LILACS) between January 1946 and July 2013 for observational studies and until December 2017 for intervention studies that evaluated the relationship between diet during pregnancy, lactation, or the first year of life and future risk of allergic or autoimmune disease. We identified 260 original studies (964,143 participants) of milk feeding, including 1 intervention trial of breastfeeding promotion, and 173 original studies (542,672 participants) of other maternal or infant dietary exposures, including 80 trials of maternal (n = 26), infant (n = 32), or combined (n = 22) interventions. Risk of bias was high in 125 (48%) milk feeding studies and 44 (25%) studies of other dietary exposures. Evidence from 19 intervention trials suggests that oral supplementation with nonpathogenic micro-organisms (probiotics) during late pregnancy and lactation may reduce risk of eczema (Risk Ratio [RR] 0.78; 95% CI 0.68–0.90; I2 = 61%; Absolute Risk Reduction 44 cases per 1,000; 95% CI 20–64), and 6 trials suggest that fish oil supplementation during pregnancy and lactation may reduce risk of allergic sensitisation to egg (RR 0.69, 95% CI 0.53–0.90; I2 = 15%; Absolute Risk Reduction 31 cases per 1,000; 95% CI 10–47). GRADE certainty of these findings was moderate. We found weaker support for the hypotheses that breastfeeding promotion reduces risk of eczema during infancy (1 intervention trial), that longer exclusive breastfeeding is associated with reduced type 1 diabetes mellitus (28 observational studies), and that probiotics reduce risk of allergic sensitisation to cow’s milk (9 intervention trials), where GRADE certainty of findings was low. We did not find that other dietary exposures—including prebiotic supplements, maternal allergenic food avoidance, and vitamin, mineral, fruit, and vegetable intake—influence risk of allergic or autoimmune disease. For many dietary exposures, data were inconclusive or inconsistent, such that we were unable to exclude the possibility of important beneficial or harmful effects. In this comprehensive systematic review, we were not able to include more recent observational studies or verify data via direct contact with authors, and we did not evaluate measures of food diversity during infancy. Our findings support a relationship between maternal diet and risk of immune-mediated diseases in the child. Maternal probiotic and fish oil supplementation may reduce risk of eczema and allergic sensitisation to food, respectively.

29 March 2016 in BMJ
Verified
Journal Article
Open access
PDF file
ADAnnemarie B Docherty
Annemarie B Docherty
RORob O’donnell
Rob O’donnell
SBSusan Brunskill
Susan Brunskill
MTMarialena Trivella
Marialena Trivella
CDCarolyn Doree
Carolyn Doree
SSSimon J Stanworth
Simon J Stanworth
Objective To compare patient outcomes of restrictive versus liberal blood transfusion strategies in patients with cardiovascular disease not undergoing cardiac surgery. Design Systematic review and meta-analysis. Data sources Randomised controlled trials involving a threshold for red blood cell transfusion in hospital. We searched (to 2 November 2015) CENTRAL, Medline, Embase, CINAHL, PubMed, LILACS, NHSBT Transfusion Evidence Library, ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, ISRCTN Register, and EU Clinical Trials Register. Authors were contacted for data whenever possible. Trial selection Published and unpublished randomised controlled trials comparing a restrictive with liberal transfusion threshold and that included patients with cardiovascular disease. Data extraction and synthesis Data extraction was completed in duplicate. Risk of bias was assessed using Cochrane methods. Relative risk ratios with 95% confidence intervals were presented in all meta-analyses. Mantel-Haenszel random effects models were used to pool risk ratios. Main outcome measures 30 day mortality, and cardiovascular events. Results 41 trials were identified; of these, seven included data on patients with cardiovascular disease. Data from a further four trials enrolling patients with cardiovascular disease were obtained from the authors. In total, 11 trials enrolling patients with cardiovascular disease (n=3033) were included for meta-analysis (restrictive transfusion, n=1514 patients; liberal transfusion, n=1519). The pooled risk ratio for the association between transfusion thresholds and 30 day mortality was 1.15 (95% confidence interval 0.88 to 1.50, P=0.50), with little heterogeneity (I2=14%). The risk of acute coronary syndrome in patients managed with restrictive compared with liberal transfusion was increased (nine trials; risk ratio 1.78, 95% confidence interval 1.18 to 2.70, P=0.01, I2=0%). Conclusions The results show that it may not be safe to use a restrictive transfusion threshold of less than 80 g/L in patients with ongoing acute coronary syndrome or chronic cardiovascular disease. Effects on mortality and other outcomes are uncertain. These data support the use of a more liberal transfusion threshold (>80 g/L) for patients with both acute and chronic cardiovascular disease until adequately powered high quality randomised trials have been undertaken in patients with cardiovascular disease. Registration PROSPERO CRD42014014251.

1 May 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
AOAyodele Odutayo
Ayodele Odutayo
MDMichael J R Desborough
Michael J R Desborough
MTMarialena Trivella
Marialena Trivella
ASAdrian J Stanley
Adrian J Stanley
CDCarolyn Dorée
Carolyn Dorée
VJVipul Jairath
Vipul Jairath